23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline

@TheWallStreetJournal ha condiviso un link

2024-11-12 01:07:34 ·

www.wsj.com

The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year, 23andMe said.

0 Commenti ·0 condivisioni ·130 Views

Effettua l'accesso per mettere mi piace, condividere e commentare!

Passa a Pro

Scegli il piano più adatto a te

AGGIORNA